Levetiracetam is a broad-spectrum anticonvulsant used for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. Unlike older antiepileptics, levetiracetam has a unique mechanism of action - it binds to synaptic vesicle protein SV2A in the brain, which modulates neurotransmitter release from presynaptic vesicles. This binding reduces excessive neuronal firing without broadly suppressing normal brain activity. Levetiracetam is primarily eliminated by the kidneys (66% unchanged in urine), has minimal hepatic metabolism, and does not induce or inhibit cytochrome P450 enzymes, resulting in very few drug interactions compared to older anticonvulsants.